Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database
Therapy with 2 immune checkpoint inhibitors was associated with an increased risk of myocarditis compared with monotherapy, with most cases occurring in the first 6 months of therapy.
Authors
- Alistair C Lindsay (ORCID: https://orcid.org/0000-0002-2150-9389)
- Sebastian Schneeweiß (ORCID: https://orcid.org/0000-0003-2575-467X)
- Alexander M. Walker (ORCID: https://orcid.org/0000-0001-9738-5127)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1161/jaha.124.035689
- Citations
- 7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Brigham and Women's Hospital
- Hamilton Health Sciences Foundation
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute of Arthritis and Musculoskeletal and Skin Diseases